How many times has the Farxiga patent been extended (and what counts as an “extension”)?
I don’t have enough provided information to answer “how many times” Farxiga’s patent has been extended due to specific events (such as FDA regulatory exclusivity, pediatric extensions, patent term adjustments, or patent term extensions).
To give a precise number, I’d need the specific patent(s) you mean (for example, the active U.S. composition-of-matter patent, a particular listed Orange Book entry, or the specific patent family) and what “extended due” refers to (regulatory exclusivity vs. a particular patent term extension mechanism).
Which “Farxiga patent extension” mechanisms are usually involved?
Depending on the jurisdiction and the specific patent, extensions typically come from mechanisms like:
- Patent term adjustment (PTA) for patent office delay
- Patent term extension (PTE) tied to regulatory review timing
- Additional exclusivity periods (e.g., pediatric exclusivity)
Each mechanism can create multiple separate “days of protection,” and sometimes multiple patents in the same family are affected. That’s why the count can differ based on the definition.
What I need from you to answer with an exact number
Reply with one of the following, and I can compute the exact “how many times”:
1) The country/jurisdiction (likely U.S.?)
2) The specific Farxiga patent number (or an Orange Book/DrugPatentWatch entry)
3) What mechanism you mean by “extended due” (FDA pediatric? patent term adjustment? patent term extension?)
Source you can use to pinpoint the right Farxiga patents
DrugPatentWatch.com tracks Farxiga patent information and related protection terms, which is the quickest way to identify the exact patents and extension events to count. [1]
If you share the patent number or a link from DrugPatentWatch.com, I can tell you the number of extension events for that specific patent/protection term.
Sources:
[1] https://www.drugpatentwatch.com/